SPOTLIGHT -
ECT and Ketamine/Esketamine: Guiding Clinical Practice
ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.
Adjunctive Cariprazine in Treating Major Depressive Disorder
This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.
Using Brain Science to Develop Better, Safer, More Effective Treatments
Deep brain stimulation for substance use disorders when everything else fails, the history of the ACNP, and more.
The First Step: A Schizophrenia-Specific Intervention for Nicotine Use
Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.
Amotivation in Individuals with Schizophrenia: Exciting Research Ideas at ACNP 2023 Annual Meeting
Exciting research ideas are stirring at the ACNP 2023 Annual Meeting.
Neurosteroid Therapeutics “Offer Great Promise” in Postpartum Depression
Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.
Takeaways on Cognitive Impairment in Schizophrenia from ACNP 2023 Annual Meeting
Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!
“A Little Bit Science, A Little Bit Manifesto”: Deep Brain Stimulation in Psychiatry
DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.
Making a Real Difference: Biomarkers and Novel Treatment Development for Serious Mental Illness
Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?
Navacaprant: A Hot Topic at the ACNP 2023 Annual Meeting
Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.
Eating Disorders and Emerging Neuroscience
Don't miss this ACNP 2023 Annual Meeting session!
Identifying and Assessing Suicide Risk Amidst Record High of Suicide Deaths
Michael F. Myers, MD provided tips and advice to clinicians who might be dealing with a patient contemplating suicide.
Understanding Alcohol Misuse in Women
“Epidemiological surveys have shown that gender gaps and alcohol consumption and alcohol-related harms are narrowing for women and men—such that alcohol is growing women’s health issue.”
How Can You Learn and Benefit From the Field of Emergency Psychiatry?
Tony Thrasher, DO, DFAPA, shared his thoughts on emergency psychiatry: an honor and a great stressor.
To BD or Not to Diagnose BD: That's the Question
What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.
Getting Started With Buprenorphine
An expert addresses some common concerns about the drug and some effective ways clinicians can initiate the treatment at the 2023 Annual Psychiatric Times™ World CME Conference.
Beyond Benzos: Treatment Options for Insomnia
What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.
“Clozapine Keeps Patients Alive”: Starting This Antipsychotic Sooner
Here’s why you should initiate clozapine sooner in patients with treatment-resistant schizophrenia.
A Practical Guide to Eliciting Positive Change in Patients Through Motivational Interviewing
An expert discusses motivational interviewing at the 2023 Annual Psychiatric Times™ World CME Conference.
The Earlier, the Better: Long-Acting Injectable Antipsychotics for Managing Schizophrenia
Sanjai Rao, MD, shared best practices for utilizing long-acting injectable antipsychotics at the 2023 Psychiatric Times World CME Conference.
Deep Dive on Dementia at the 2023 Psychiatric Times World CME Conference
Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!
Orexin: The New Kid on the Insomnia Block
The newest class of medications to treat insomnia have many advantages.
Updates on Schizophrenia at the 2023 Psychiatric Times World CME Conference
Don't miss updates on schizophrenia at our conference, beginning at 3:10PM EST!
Why You Should Attend the 2023 Psychiatric Times World CME Conference
Our Editor in Chief explains why you should attend our conference!
How Do Treatments for Bipolar Disorder and SUD Affect One Another?
An expert discusses the connections between the 2 highly comorbid diseases and some ways to effectively treat both diseases simultaneously.
Positive Top-Line Phase 3 Data on Novel ADHD Treatment, CTx-1301
New positive data for novel ADHD treatment.
EMPOWERing the Next Generation
An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.
Keeping Up With the Times
Have you registered for the 2023 Annual Psychiatric Times World CME Conference?
Paliperidone Palmitate for Schizophrenia: Research on New Innovative Treatment for Unmet Needs
Christoph Correll, MD, shares more on paliperidone palmitate 6-month for the treatment of schizophrenia.
Study Supports Long-Term Efficacy of Esketamine Nasal Spray in Patients With TRD
Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.